...Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright's 24th Annual Global Investment Hybrid Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright. It's my pleasure to introduce our next presenter. I'd like to welcome Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene-editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies. So maybe if we could just begin with an overview of Precision's ARCUS platform, how it's differentiated versus other approaches in the field such as CRISPR. Michael Amoroso ...